Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)

To prospectively investigate the survival benefit of para-aortic lymphadenectomy, we launched a new study, the JCOG1412. This is a randomized Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone. Patients corresponding to possible FIGO...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of clinical oncology 2017-10, Vol.47 (10), p.986-990
Main Authors: Watari, Hidemichi, Katayama, Hiroshi, Shibata, Taro, Ushijima, Kimio, Satoh, Toyomi, Onda, Takashi, Aoki, Daisuke, Fukuda, Haruhiko, Yaegashi, Nobuo, Sakuragi, Noriaki
Format: Article
Language:English
Subjects:
Adult
Aged
Endometrial Neoplasms - pathology
Endometrial Neoplasms - surgery
Endometrial Neoplasms - therapy
Female
Humans
Japan
Lymph Node Excision - methods
Lymph Nodes - pathology
Lymph Nodes - surgery
Lymphatic Metastasis - pathology
Male
Middle Aged
Pelvis - pathology
Pelvis - surgery
Prospective Studies
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To prospectively investigate the survival benefit of para-aortic lymphadenectomy, we launched a new study, the JCOG1412. This is a randomized Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone. Patients corresponding to possible FIGO Stage IB, II, IIIA, IIIB, and a part of IIIC1 are eligible for the first registration before surgery. Next, those patients without evidence of para-aortic lymph node metastasis and multiple pelvic lymph node metastasis during surgery will be included in the second registration and randomized to either the pelvic lymphadenectomy alone arm or the pelvic and para-aortic lymphadenectomy arm. After the initial surgery, patients with post-operative recurrence risks receive adjuvant chemotherapy. The primary endpoint is overall survival. Secondary endpoints include relapse-free survival, short-term surgical outcomes, adverse events related to adjuvant chemotherapy and recurrence patterns. This trial has been registered at the UMIN Clinical Trials Registry [http://www.umin.ac.jp/ctr/index.htm] as UMIN000025399.
ISSN:0368-2811
1465-3621
DOI:10.1093/jjco/hyx108